Your browser doesn't support javascript.
Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab.
Blauvelt, Andrew; Pink, Andrew; Worm, Margitta; Langley, Richard G B; Elewski, Boni E; Gjerum, Le; Guttman-Yassky, Emma.
  • Blauvelt A; Oregon Medical Research Center, Portland.
  • Pink A; St John's Institute of Dermatology, Guy's Hospital, London, United Kingdom.
  • Worm M; Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Langley RGB; Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Elewski BE; Department of Dermatology, The University of Alabama at Birmingham, Birmingham.
  • Gjerum L; LEO Pharma, Ballerup, Denmark.
  • Guttman-Yassky E; Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
JAMA Dermatol ; 158(11): 1327-1330, 2022 Nov 01.
Article in English | MEDLINE | ID: covidwho-2058992
This case series describes the outcomes of COVID-19 and SARS-CoV-2 vaccination in patients with atopic dermatitis who have been treated with tralokinumab.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis, Atopic / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Language: English Journal: JAMA Dermatol Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dermatitis, Atopic / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Language: English Journal: JAMA Dermatol Year: 2022 Document Type: Article